Tofacitinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and NICE (England), among others, recommended or restricted tofacitinib, while CIPM (Spain) did not recommend it.
PBAC (Australia) has been easier on tofacitinib than on its own caseload: it refused 0 of 6 decisive submissions here (0%), against a base rate of 24% across everything it has assessed.
Assessment has run over 11 years, from 2015 at PBAC (Australia) to 2026 at PBAC (Australia).
DMC (Denmark) changed its position: recommended on 7 Feb 2018, restricted by 25 Mar 2020.
Every one of the eight highest-volume agencies in this archive has a record for tofacitinib.
The file is active: 8 of 60 records date from 2023 or later.
The programme is broad: 22 distinct indication wordings are recorded for tofacitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
9 of these 60 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess tofacitinib, in 2015; CIPM (Spain) did not open a file until 7 Apr 2021 — a wide spread of 5.8 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 10 years in total.
Restriction is doing real work here: 14 of 48 decisive outcomes narrowed tofacitinib to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), DMC (Denmark) and NICE (England) among others.
11 of the 13 agencies here assessed tofacitinib more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
tofacitinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tofacitinib reads 28 recommended, 14 restricted, 6 not recommended and 5 deferred to NICE, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Rheumatoid arthritis (RA)Psoriatic arthritis (PsA) | Recommended | source |
| AOTMIT (Poland) | 4 Jun 2024 | programu lekowego „Leczenie chorych z aktywną postacią reumatoidalnego zapalenia stawów i młodzieńczego idiopatycznego z… | recommended conditionally | source |
| NICE (England) | 18 Oct 2023 | NICE TA920 | recommended | source |
| NYE METODER (Norway) | 17 Oct 2022 | Behandling av aktiv polyartikulær juvenil idiopatisk artritt (RF-positiv eller RF-negativ polyartritt og forlenget oligo… | introduced | source |
| HAS (France) | 20 Mar 2019 | Indication extension | SMR insufficient · ASMR IV | source |
55 further decisions for tofacitinib, across 13 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 39 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 60 decisions for tofacitinib from 13 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.